First Canadian Participant Dosed in ARGUS Trial, A Phase 2 Potentially Pivotal Study of EPX-100 Treatment of Dravet Syndrome
June 01, 2022 04:00 ET
|
Epygenix Therapeutics
PARAMUS, N.J., June 01, 2022 (GLOBE NEWSWIRE) -- Epygenix Therapeutics, a clinical-stage biopharmaceutical company focused on genetically screening, discovering and developing safe, effective and...